F I N E
With the smallest particles for the correction of very thin, superficial lines. Injected in the upper part of dermis, for correction of thin superficial lines, such as Frown lines, Forehead lines, Neck lines
Recommended indications
This superficial lines
Where to inject
Upper part of dermis
Composition
20mg/ml HA
Particle Size
0.10-0.15mm
Approximate number of gel Particles per ml
∼500,000/ml
Duration
6-12 months
Use
Single
HA Origin
Non Animal
Storage
Room Temperature/up to 30’C (86’F)
Volume
1ml
D E R M
Medium particle size for moderate wrinkles. Injected in the middle part of dermis, for treatment of moderate wrinkle, such as Forehead, Neck, Nose, Chin, Lip, Earlobe
Recommended indications
Moderate Wrinkles
Where to inject
Middle part of dermis
Composition
20mg/ml HA
Particle Size
0.15-0.28mm
Approximate number of gel Particles per ml
∼200,000/ml
Duration
6-12 months
Use
Single
HA Origin
Non Animal
Storage
Room Temperature/up to 30’C (86’F)
Volume
1ml
D E E P
Larger particles for deep folds. Injected in the deep layer of dermis, for correction of deep facial wrinkles and folds, such as Nasolabial folds, Lip, Chin, Earlobe, Temple, Cheek
Recommended indications
Deep facial wrinkels and folds
Where to inject
Deep layer of dermis
Composition
20mg/ml HA
Particle Size
0.28-0.50mm
Approximate number of gel Particles per ml
∼100,000/ml
Duration
6-12 months
Use
Single
HA Origin
Non Animal
Storage
Room Temperature/up to 30’C (86’F)
Volume
1ml
D E E P E R
Larger particles for deep folds. Injected in the deep dermis or subcutaneous tissue shallow, for treatment of deep facial wrinkles and folds, such as Nasolabial folds, Temple, Cheek, Breast, Buttock
Recommended indications
Deep facial wrinkels and folds
Where to inject
Deep dermis or subcutaneous tissue shallow
Composition
20mg/ml HA
Particle Size
0.50-1.00mm
Approximate number of gel Particles per ml
∼10,000/ml
Duration
9-12 months
Use
Single
HA Origin
Non Animal
Storage
Room Temperature/up to 30’C (86’F)
Volume
1ml
Important Safety Information
enAvant Fine is only intended for use as an intradermal implant.
Do not inject intravascularly. As for other injectable medical devices, inadvertent injection into blood vessels
could potentially lead to vascular occlusion, ischemia and necrosis. Aspiration prior to injection is recommended.
If blanching is observed, i.e, the overlying skin turns a whitish color, the injection should be stopped at once and
the area massaged until it returns to a normal color.
Do not use in patients with bleeding disorders or in patients who are taking thrombolytics or anticoagulants.
Do not resterilize enAvant
Do not mix with other products prior to injection of the device.
Contraindications
• Pregnant women, lactating women, and minors should be used with caution.
• Patients with a history of severe allergic reactions and patients with multiple history of severe allergies are contraindicated.
• Patients with abnormal clotting mechanisms or patients who have been treated with thrombolytics, anticoagulants, or platelet aggregation inhibitors within two weeks are contraindicated.
• Disabled in the following situations:
The site where permanent fillers have been injected is banned; the site where non-permanent fillers have been used within 6 months has been disabled; the site where fillers have been injected but the type is not clear has been banned; active dermatoses, inflammations, infections and related diseases The site or its vicinity is disabled.
